GlobeNewswire Inc | Oct 7, 2021 08:55AM EDT

October 07, 2021

KELOWNA, British Columbia, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Allied Corp. ("Allied" or the Company) (OTCQB: ALID) is pleased to announce the signing of supply contracts for the 2022 calendar. Allied will be only providing cannabis flower after the Colombian government allows it and will provide supply only to countries where it is legal to sell into (for example, the United States only allows for THC levels to be less than 0.3%).

The first contract that was signed on September 30, 2021 was for a supply volume of 85,000 kilograms of dried cannabis flower for the 2022 calendar year. This was signed with a partner that has over 25 years experience in providing pharmaceutical, medical, dental and consumable medical products to medical wholesalers, distributors and healthcare establishments in international markets.

The second contract was signed on September 27th, 2021 for a supply volume of 40,000 kilograms of dried cannabis flower for the 2022 calendar year. This contract was signed with a partner that was established in 2017 for import/export services, sourcing and supply chain management in the global agricultural and pharma industries.

The third contract was signed on September 28, 2021 for a supply volume of 24,000 kilograms of dried cannabis flower for the 2022 calendar year. This contract was signed with a partner that is a full service global cannabis sales firm with expertise and network that spans many international markets. This company specializes in product procurement and sales for medical cannabis and hemp markets across the globe. This contract positions Allied to offer its product for sale on an ongoing basis across current legal markets in Australia, United States, Canada, South America, Europe, the Middle East, Africa, and Asia.

As Colombia continues to move towards the ability to export cannabis flower to countries where it is legal to do so, these contracts point to the demand that the global cannabis market is asking for. We believe that these supply contracts are just the start of Allieds production volumes. We harvest on a weekly basis and by nature of this we believe that we will be able to provide rolling supply that is harvested fresh every week. We also continue to build relationships with buyers in many different countries around the globe and, through this, we believe that we are ready to supply the market demand in many international markets where it is legal to do so, said Mr. Calum Hughes, CEO and Chairman of Allied Corp.

About Allied Corp. - https://allied.health/

Allied Corp.is an international cannabis company with its main production center in Colombia and is one of the few companies that has exported from Colombia internationally. In preparation for the possible legalization of cannabis by the US Federal Government, Allied also has the option to purchase a US cannabis license in the US (Nevada) exercisable if such were to happen. In addition to this, Allied has three CBD-brands to market with products selling in the United States. Lastly, Allied has both Cannabinoid and psilocybin products in the pharmaceutical development track seeking pharma drug indications for depression, anxiety and PTSD.

Investor Relations:ir@allied.health1-877-255-4337

Forward-Looking Statements:This press release contains forward-looking information within the meaning of applicable securities laws in Canada or forward-looking statements made pursuant to the safe harbour provisions of the United States Private Securities Litigation Reform Act of 1995 (collectively, forward-looking information). Forward-looking information may relate to the Companys future outlook and anticipated events, plans or results, and may include information regarding the Companys objectives, goals, strategies, future revenue or performance and capital expenditures, and other information that is not historical information. Forward-looking information can often be identified by the use of terminology such as believe, anticipate, plan, expect, pending, in process, intend, estimate, project, may, will, should, would, could, can, the negatives thereof, variations thereon and similar expressions. The forward-looking information contained in this press release is based on the Companys opinions, estimates and assumptions in light of managements experience and perception of historical trends, current conditions and expected future developments, as well as other factors that management currently believes are appropriate and reasonable in the circumstances. Forward looking statements in this press release include the following: that Allied is leveraging the conditions in its Colombia grow operation and future Kelowna location to support its Research and Development efforts; that Allied is making important strides forward to position itself as a leader in the medical cannabis space, that Allied intends to make a series of proposed trademark and other intellectual property protection filings, as part of the Companys Intellectual Property and Pharma Development (IP&PD) Strategy, statements respecting the joint development, manufacturing, and introduction of TACTICAL RELIEF branded products, and the use of proceeds from the offering of convertible notes.

There can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct. Risk factors that could cause actual results to differ materially from forward-looking information in this release include: the Companys exposure to legal and regulatory risk; the effect of the legalization of adult-use cannabis in Canada and Colombia on the medical cannabis industry is unknown and may significantly and negatively affect the Companys medical cannabis business; that the medical benefits, viability, safety, efficacy, dosing and social acceptance of cannabis are not as currently expected; that adverse changes or developments affecting the Companys main or planned facilities may have an adverse effect on the Company; that the medical cannabis industry and market may not continue to exist or develop as anticipated or the Company may not be able to succeed in this market; risks related to completion of the greenhouse construction in Colombia, risks related to market competition; risks related to the proposed adult-use cannabis industry and market in Canada and Colombia including the Companys ability to enter into or compete in such markets; that the Company has a limited operating history and a history of net losses and that it may not achieve or maintain profitability in the future; risks related to the Companys current or proposed international operations; risks related to future third party strategic alliances or the expansion of currently existing relationships with third parties; that the Company may not be able to successfully identify and execute future acquisitions or dispositions or successfully manage the impacts of such transactions on its operations; risks inherent to the operation of an agricultural business; that the Company may be unable to attract, develop and retain key personnel; risks resulting from significant interruptions to the Companys access to certain key inputs such as raw materials, electricity, water and other utilities; that the Company may be unable to transport its cannabis products to patients in a safe and efficient manner; risks related to recalls of the Companys cannabis products or product liability or regulatory claims or actions involving the Companys cannabis products; risks related to the Companys reliance on pharmaceutical distributors; that the Company, or the cannabis industry more generally, may receive unfavourable publicity or become subject to negative consumer or investor perception; that certain events or developments in the cannabis industry more generally may impact the Companys reputation or its relationships with customers or suppliers; that the Company may not be able to obtain adequate insurance coverage in respect of the risks that it faces, that the premiums for such insurance may not continue to be commercially justifiable or that there may be coverage limitations and other exclusions which may result in such insurance not being sufficient; that the Company may become subject to liability arising from fraudulent or illegal activity by its employees, contractors, consultants and others; that the Company may experience breaches of security at its facilities or losses as a result of the theft of its products; risks related to the Companys information technology systems; that the Company may be unable to sustain its revenue growth and development; that the Company may be unable to expand its operations quickly enough to meet demand or manage its operations beyond their current scale; that the Company may be unable to secure adequate or reliable sources of necessary funding; risks related to, or associated with, the Companys exposure to reporting requirements; risks related to conflicts of interest; risks related to fluctuations in foreign currency exchange rates; risks related to the Companys potential exposure to greater-than-anticipated tax liabilities; risks related to the protection and enforcement of the Companys intellectual property rights, or the intellectual property that it licenses from others; that the Company may become subject to allegations that it or its licensors are in violation of the intellectual property rights of third parties; that the Company may not realize the full benefit of the clinical trials or studies that it participates in; that the Company may not realize the full benefit of its licenses if the licensed material has less market appeal than expected and the licenses may not be profitable; as well as any other risks that may be further described in and the risk factors discussed in the Company's continuous disclosure including its Management's Discussion and Analysis sections in its Quarterly Reports on Form 10-Q, Annual Reports on Form 10-K and Current Reports on Form 8-K filed under the Company's profile at www.sec.gov.

Although management has attempted to identify important risk factors that could cause actual results to differ materially from those contained in the forward-looking information in this presentation, there may be other risk factors not presently known to the Company or that the Company presently believes are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking information in this presentation. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers and viewers should not place undue reliance on forward-looking information, which speaks only as of the date made. The forward-looking information contained in this release represents the Companys expectations as of the date of this release or the date indicated, regardless of the time of delivery of the presentation. The Company disclaims any intention, obligation or undertaking to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required under applicable securities laws.